[HTML][HTML] Cognitive function in a randomized trial of evolocumab
RP Giugliano, F Mach, K Zavitz, C Kurtz… - … England Journal of …, 2017 - Mass Medical Soc
Background Findings from clinical trials of proprotein convertase subtilisin–kexin type 9
(PCSK9) inhibitors have led to concern that these drugs or the low levels of low-density
lipoprotein (LDL) cholesterol that result from their use are associated with cognitive deficits.
Methods In a subgroup of patients from a randomized, placebo-controlled trial of
evolocumab added to statin therapy, we prospectively assessed cognitive function using the
Cambridge Neuropsychological Test Automated Battery. The primary end point was the …
(PCSK9) inhibitors have led to concern that these drugs or the low levels of low-density
lipoprotein (LDL) cholesterol that result from their use are associated with cognitive deficits.
Methods In a subgroup of patients from a randomized, placebo-controlled trial of
evolocumab added to statin therapy, we prospectively assessed cognitive function using the
Cambridge Neuropsychological Test Automated Battery. The primary end point was the …
以上显示的是最相近的搜索结果。 查看全部搜索结果